<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-12-03" updated="2019-12-02">
  <drugbank-id primary="true">DB11157</drugbank-id>
  <name>Anthralin</name>
  <description>Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. Adverse effects of anthralin include irritation and discoloration of the skin [A27277].&#13;
&#13;
This specific property of the molecule inspired workers to study details of its pharmacology. It is important to consider that the drug is relatively innocuous, yet effective, and systemic side effects have not been observed with this anthralin, in contrast to a wide variety of systemic and topical therapies for psoriasis [L1935]. &#13;
&#13;
Anthralin is also known as dithranol.  It is a main active ingredient in topical skin formulations for the treatment of psoriasis. Various formulations of the drug are available, including solutions, foams, and shampoos [L1979]. The chemical structure of anthralin allows for dual solubility, permitting the compound to be absorbed well through the epidermis [A27276]. &#13;
&#13;
Anthralin has also been studied in the treatment of warts, showing promising results [A32307]. Salicylic acid is frequently added to anthralin to augment the stability of anthralin and to increase its penetration and efficacy [L1979].</description>
  <cas-number>1143-38-0</cas-number>
  <unii>U8CJK0JH5M</unii>
  <average-mass>226.231</average-mass>
  <monoisotopic-mass>226.062994182</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A27276</ref-id>
        <pubmed-id>6309924</pubmed-id>
        <citation>Ashton RE, Andre P, Lowe NJ, Whitefield M: Anthralin: historical and current perspectives. J Am Acad Dermatol. 1983 Aug;9(2):173-92.</citation>
      </article>
      <article>
        <ref-id>A27277</ref-id>
        <pubmed-id>25208745</pubmed-id>
        <citation>Sehgal VN, Verma P, Khurana A: Anthralin/dithranol in dermatology. Int J Dermatol. 2014 Oct;53(10):e449-60. doi: 10.1111/j.1365-4632.2012.05611.x. Epub 2014 Sep 10.</citation>
      </article>
      <article>
        <ref-id>A32307</ref-id>
        <pubmed-id>6203313</pubmed-id>
        <citation>Flindt-Hansen H, Tikjob G, Brandrup F: Wart treatment with anthralin. Acta Derm Venereol. 1984;64(2):177-9.</citation>
      </article>
      <article>
        <ref-id>A32313</ref-id>
        <pubmed-id>15802490</pubmed-id>
        <citation>McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ: The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J. 2005 Jun;19(8):1012-4. doi: 10.1096/fj.04-2664fje. Epub 2005 Mar 31.</citation>
      </article>
      <article>
        <ref-id>A32314</ref-id>
        <pubmed-id>125665</pubmed-id>
        <citation>Diezel W, Meffert H, Sonnichsen N: [Study on the mode of action of dithranol: increased lipid peroxidation and enzyme inhibition]. Dermatologica. 1975;150(3):154-62.</citation>
      </article>
      <article>
        <ref-id>A32315</ref-id>
        <pubmed-id>10733674</pubmed-id>
        <citation>Peus D, Beyerle A, Rittner HL, Pott M, Meves A, Weyand C, Pittelkow MR: Anti-psoriatic drug anthralin activates JNK via lipid peroxidation: mononuclear cells are more sensitive than keratinocytes. J Invest Dermatol. 2000 Apr;114(4):688-92. doi: 10.1046/j.1523-1747.2000.00934.x.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L1932</ref-id>
        <title>Anthralin</title>
        <url>https://www.drugs.com/mmx/anthralin.html</url>
      </link>
      <link>
        <ref-id>L1933</ref-id>
        <title>Zithranol, PDR</title>
        <url>http://www.pdr.net/drug-summary/Zithranol-RR-anthralin-2822</url>
      </link>
      <link>
        <ref-id>L1935</ref-id>
        <title>Anthralin/dithranol in dermatology</title>
        <url>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-4632.2012.05611.x</url>
      </link>
      <link>
        <ref-id>L1936</ref-id>
        <title>PubChem, Anthralin</title>
        <url>https://pubchem.ncbi.nlm.nih.gov/compound/anthralin#section=Top</url>
      </link>
      <link>
        <ref-id>L1938</ref-id>
        <title>Zithranol-RR</title>
        <url>http://www.empr.com/zithranol-rr/drug/3423/</url>
      </link>
      <link>
        <ref-id>L1939</ref-id>
        <title>American Academy of Dermatology Recommendations</title>
        <url>https://www.aad.org/practicecenter/quality/clinical-guidelines/psoriasis/topical-therapy/recommendations-for-anthralin</url>
      </link>
      <link>
        <ref-id>L1979</ref-id>
        <title>NIH.gov Topical Therapies in psoriasis</title>
        <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518573/</url>
      </link>
      <link>
        <ref-id>L1980</ref-id>
        <title>Prophase Definition</title>
        <url>https://www.nature.com/scitable/definition/prophase-189</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Stable plaque psoriasis of the skin and scalp [L1933].&#13;
&#13;
It is also used topically in the management of psoriasis, dermatoses, and alopecia areata. Anthralin is also used in biomedical research due to its effect on EGFR autophosphorylation [L1936].</indication>
  <pharmacodynamics>&#13;
Anthralin is a natural anthraquinone derivative, anti-psoriatic and anti-inflammatory agent.  It controls skin growth by reducing the synthesis of DNA and the mitotic activity in the hyperplastic epidermis, normalizing the rate of cell proliferation and keratinization [L1936].</pharmacodynamics>
  <mechanism-of-action>&#13;
Anthralin inhibits the proliferation of keratinocytes (epidermal skin cells), prevents the action of T-cells, and promotes cell differentiation, likely through mitochondrial dysfunction. In addition, the production of free radicals may contribute to its anti-psoriatic effect [L1979]. In vitro studies demonstrate that anthralin prolongs the prophase component of mitosis for keratinocytes and leukocytes [L1932].  Prophase is the first step of mitosis, the process separating the duplicated genetic material carried in the nucleus of a parent cell into two identical daughter cells [L1980]. In vivo studies demonstrate that anthralin blocks DNA synthesis and can increase the release of reactive oxygen species [L1932].&#13;
&#13;
Anthralin is believed to normalize the rate of epidermal cell proliferation and keratinization by reducing the mitotic activity of the epidermal hyperplasia in psoriasis [L1979].&#13;
&#13;
&#13;
Anti-proliferative and anti-inflammatory effects of anthralin have been demonstrated on both psoriatic and healthy skin. The anti-proliferative effects of anthralin are thought to be due to a combination of inhibition of DNA synthesis and its strong reducing properties. The effectiveness of anthralin as an anti-psoriatic agent is partly owed to its ability to promote lipid peroxidation and reduce the concentration of endothelial adhesion molecules, which are found to be elevated in psoriatic patients [L1933], [L1979].&#13;
&#13;
Recent studies suggest that its ability to prevent T-lymphocyte activation and normalize keratinocyte differentiation may occur by a direct effect on mitochondria [A32313].</mechanism-of-action>
  <toxicity>Some mild adverse effects include alterations in nail coloring, hair coloring, increase in photosensitivity, and skin irritation [L1933].&#13;
&#13;
The most common side effects of anthralin are skin irritation and staining of nearby skin, nails, clothing, and other objects that come in contact with the treated patient. The incidence of irritation of psoriatic/surrounding healthy skin is higher in patients who leave anthralin on the skin without rinsing than in those who use short-contact therapy of 2 hours or less, followed by rinsing [L1939].&#13;
&#13;
If the psoriatic plaques are well circumscribed, the surrounding normal skin may be protected by the use of a coating agent such as zinc oxide ointment. Anthralin should be applied cautiously to the face and intertriginous areas due to the risk of severe skin irritation [L1979].&#13;
&#13;
There is no current evidence of any long-term anthralin toxicity related either to skin exposure or to systemic issues [L1939].&#13;
Some long-term studies in mice have demonstrated anthralin to be tumorigenic in mouse skin. This carcinogenic potential has not been thoroughly evaluated. Tumorigenic and carcinogenic effects of anthralin have not been observed in humans at this time  [L1932]. Anthralin is classified as FDA pregnancy risk category C drug [L1979]. It is not known if anthralin can cause fetal harm when administered during gestation. Because of the lack of evidential human data, anthralin should be used during pregnancy only when clearly required [L1933].</toxicity>
  <metabolism>Anthralin is administered topically. Although the extent of systemic absorption after topical application has not been determined, no traces of anthraquinone metabolites were detected in the urine of treated subjects in a limited clinical study of anthralin cream [L1932], [L1933].&#13;
&#13;
Anthralin does not inhibit hepatic microsomal enzyme activity [L1933].</metabolism>
  <absorption>Anthralin penetrates damaged skin and psoriatic lesions faster and to a greater extent than normal skin, likely due to increased vascularity of psoriatic lesions [L1932].&#13;
&#13;
&#13;
&#13;
</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as anthracenes. These are organic compounds containing a system of three linearly fused benzene rings.</description>
    <direct-parent>Anthracenes</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Anthracenes</class>
    <subclass/>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>1-hydroxy-4-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>Aryl ketones</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Vinylogous acids</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>1-hydroxy-4-unsubstituted benzenoid</substituent>
    <substituent>Anthracene</substituent>
    <substituent>Aromatic homopolycyclic compound</substituent>
    <substituent>Aryl ketone</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Ketone</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Vinylogous acid</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="inn">Dithranol</synonym>
    <synonym language="spanish" coder="">Ditranol</synonym>
  </synonyms>
  <products>
    <product>
      <name>Anthraforte 1 Ointment 1%</name>
      <labeller>Medican Technologies Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00566756</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on>2014-09-02</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anthraforte 2 Ointment 2%</name>
      <labeller>Medican Technologies Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00566748</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1984-12-31</started-marketing-on>
      <ended-marketing-on>2014-09-02</ended-marketing-on>
      <dosage-form>Ointment</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anthranol Cream 0.1%</name>
      <labeller>Medican Technologies Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00537594</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on>2014-09-02</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anthranol Cream 0.2%</name>
      <labeller>Medican Technologies Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00537608</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on>2014-09-02</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anthranol Cream 0.4%</name>
      <labeller>Medican Technologies Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00537616</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1982-12-31</started-marketing-on>
      <ended-marketing-on>2000-06-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Anthrascalp Lotion 0.4%</name>
      <labeller>Medican Technologies Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00695351</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1987-12-31</started-marketing-on>
      <ended-marketing-on>2014-09-02</ended-marketing-on>
      <dosage-form>Lotion</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Dritho-creme Hp</name>
      <labeller>Summers Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>11086-037</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-01-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>1 g/100g</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Micanol 3% Cream</name>
      <labeller>Canderm G.P.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02238160</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-09-01</started-marketing-on>
      <ended-marketing-on>2004-07-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Micanol Cream</name>
      <labeller>Canderm G.P.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02233053</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1998-05-06</started-marketing-on>
      <ended-marketing-on>2004-07-30</ended-marketing-on>
      <dosage-form>Cream</dosage-form>
      <strength/>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Zithranol</name>
      <labeller>Elorac, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42783-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-03-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Shampoo</dosage-form>
      <strength>1 g/100g</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Zithranol-RR</name>
      <labeller>Elorac, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42783-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>.012 g/1g</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Zithranol-RR</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Zithranol</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Dritho-creme Hp</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Anthranol Cream 0.1%</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Anthranol Cream 0.2%</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Anthranol Cream 0.4%</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Micanol Cream</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Anthraforte 2 Ointment 2%</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Anthraforte 1 Ointment 1%</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Micanol 3% Cream</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
    <mixture>
      <name>Anthrascalp Lotion 0.4%</name>
      <ingredients>Anthralin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anthracenes</category>
      <mesh-id>D000873</mesh-id>
    </category>
    <category>
      <category>Antipsoriatics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antipsoriatics for Topical Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antracen Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Ointment</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Lotion</form>
      <route>Topical</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>1 g/100g</strength>
    </dosage>
    <dosage>
      <form>Shampoo</form>
      <route>Topical</route>
      <strength>1 g/100g</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>.012 g/1g</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="D05AC01">
      <level code="D05AC">Antracen derivatives</level>
      <level code="D05A">ANTIPSORIATICS FOR TOPICAL USE</level>
      <level code="D05">ANTIPSORIATICS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
    <atc-code code="D05AC51">
      <level code="D05AC">Antracen derivatives</level>
      <level code="D05A">ANTIPSORIATICS FOR TOPICAL USE</level>
      <level code="D05">ANTIPSORIATICS</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB11157.pdf?1522271402</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.73</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-3.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.84e-01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>1,8-dihydroxy-9,10-dihydroanthracen-9-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>anthralin</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>226.231</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>226.062994182</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>OC1=CC=CC2=C1C(=O)C1=C(O)C=CC=C1C2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C14H10O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C14H10O3/c15-10-5-1-3-8-7-9-4-2-6-11(16)13(9)14(17)12(8)10/h1-6,15-16H,7H2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NUZWLKWWNNJHPT-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>57.53</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>64.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>23.12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>8.47</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-5.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>not soluble in water</value>
      <source>MSDS</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>178-182 °C</value>
      <source>MSDS</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>9362</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>37510</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>2202</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347827926</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C06831</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>2117</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50041802</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Dithranol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL46469</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0009063</id>
      <name>Keratin, type II cytoskeletal 2 epidermal</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32313</ref-id>
            <pubmed-id>15802490</pubmed-id>
            <citation>McGill A, Frank A, Emmett N, Turnbull DM, Birch-Machin MA, Reynolds NJ: The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria. FASEB J. 2005 Jun;19(8):1012-4. doi: 10.1096/fj.04-2664fje. Epub 2005 Mar 31.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P35908" source="Swiss-Prot">
        <name>Keratin, type II cytoskeletal 2 epidermal</name>
        <general-function>Probably contributes to terminal cornification. Associated with keratinocyte activation, proliferation and keratinization.</general-function>
        <specific-function>Cytoskeletal protein binding</specific-function>
        <gene-name>KRT2</gene-name>
        <locus>12q13.13</locus>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>65432.65</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6439</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35908</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>K22E_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CK-2e</synonym>
          <synonym>Cytokeratin-2e</synonym>
          <synonym>Epithelial keratin-2e</synonym>
          <synonym>K2e</synonym>
          <synonym>Keratin-2 epidermis</synonym>
          <synonym>Keratin-2e</synonym>
          <synonym>KRT2A</synonym>
          <synonym>KRT2E</synonym>
          <synonym>Type-II keratin Kb2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0049838|Keratin, type II cytoskeletal 2 epidermal
MSCQISCKSRGRGGGGGGFRGFSSGSAVVSGGSRRSTSSFSCLSRHGGGGGGFGGGGFGS
RSLVGLGGTKSISISVAGGGGGFGAAGGFGGRGGGFGGGSSFGGGSGFSGGGFGGGGFGG
GRFGGFGGPGGVGGLGGPGGFGPGGYPGGIHEVSVNQSLLQPLNVKVDPEIQNVKAQERE
QIKTLNNKFASFIDKVRFLEQQNQVLQTKWELLQQMNVGTRPINLEPIFQGYIDSLKRYL
DGLTAERTSQNSELNNMQDLVEDYKKKYEDEINKRTAAENDFVTLKKDVDNAYMIKVELQ
SKVDLLNQEIEFLKVLYDAEISQIHQSVTDTNVILSMDNSRNLDLDSIIAEVKAQYEEIA
QRSKEEAEALYHSKYEELQVTVGRHGDSLKEIKIEISELNRVIQRLQGEIAHVKKQCKNV
QDAIADAEQRGEHALKDARNKLNDLEEALQQAKEDLARLLRDYQELMNVKLALDVEIATY
RKLLEGEECRMSGDLSSNVTVSVTSSTISSNVASKAAFGGSGGRGSSSGGGYSSGSSSYG
SGGRQSGSRGGSGGGGSISGGGYGSGGGSGGRYGSGGGSKGGSISGGGYGSGGGKHSSGG
GSRGGSSSGGGYGSGGGGSSSVKGSSGEAFGSSVTFSFR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0049839|Keratin, type II cytoskeletal 2 epidermal (KRT2)
ATGAGTTGTCAGATCTCTTGCAAATCTCGAGGAAGAGGAGGAGGTGGAGGAGGATTCCGG
GGCTTCAGCAGCGGCTCAGCTGTGGTGTCTGGTGGAAGCCGGAGATCAACTTCCAGCTTC
TCCTGCTTGAGCCGCCATGGTGGTGGTGGCGGGGGCTTCGGTGGAGGCGGCTTTGGCAGT
CGGAGTCTTGTTGGCCTTGGAGGGACCAAGAGCATCTCCATTAGTGTGGCTGGAGGAGGT
GGTGGCTTTGGCGCCGCTGGTGGATTTGGTGGCAGAGGAGGTGGTTTTGGAGGCGGCAGC
AGCTTTGGAGGTGGCAGCGGCTTCAGTGGTGGTGGTTTCGGTGGAGGCGGCTTTGGTGGA
GGCCGCTTTGGAGGTTTTGGGGGCCCTGGTGGTGTTGGAGGTTTAGGGGGTCCTGGTGGC
TTTGGGCCTGGAGGATACCCTGGTGGCATCCACGAAGTCTCTGTCAACCAGAGCCTCCTG
CAGCCTCTCAACGTGAAAGTTGACCCAGAGATCCAGAATGTGAAGGCCCAAGAGCGTGAG
CAGATCAAAACTCTCAACAACAAATTTGCCTCCTTCATTGACAAGGTGCGGTTCTTGGAG
CAGCAGAACCAGGTGTTACAGACCAAATGGGAGCTGCTACAACAAATGAATGTTGGCACC
CGCCCCATCAACCTGGAGCCCATCTTCCAGGGGTATATCGACAGCCTCAAGAGATATCTG
GATGGGCTCACTGCAGAAAGAACATCACAGAATTCAGAGCTGAATAACATGCAGGATCTT
GTGGAGGATTATAAGAAGAAGTATGAGGATGAAATCAATAAGCGCACAGCTGCTGAGAAT
GATTTTGTGACGCTTAAAAAGGACGTGGACAATGCCTACATGATAAAGGTGGAGTTGCAG
TCCAAGGTGGACCTGCTGAACCAGGAAATTGAGTTTCTGAAAGTTCTCTATGATGCGGAG
ATATCCCAGATACATCAGAGTGTCACTGACACCAACGTCATCCTCTCCATGGACAACAGC
CGCAACCTGGACTTGGATAGCATCATCGCCGAGGTCAAGGCCCAGTATGAGGAGATCGCC
CAGAGGAGCAAGGAAGAAGCGGAGGCCCTGTACCACAGCAAGTATGAGGAGCTCCAGGTG
ACTGTCGGGAGACATGGAGACAGCCTGAAAGAGATCAAGATAGAGATCAGCGAGCTGAAC
CGCGTGATCCAGAGGCTGCAGGGGGAGATCGCACATGTGAAGAAGCAGTGTAAGAATGTG
CAAGATGCCATCGCAGATGCCGAGCAGCGTGGGGAGCATGCCCTCAAGGATGCCAGGAAC
AAGTTGAATGACCTGGAGGAGGCCCTGCAGCAGGCCAAGGAGGACTTGGCGCGGCTGCTG
CGTGACTACCAGGAGCTGATGAACGTGAAGCTGGCCCTAGATGTGGAGATCGCCACCTAC
CGCAAACTGCTGGAGGGCGAGGAGTGCAGGATGTCTGGAGACCTCAGCAGCAATGTGACT
GTGTCTGTGACAAGCAGCACCATTTCATCAAATGTGGCATCCAAGGCTGCCTTTGGAGGT
TCTGGAGGTAGAGGGTCCAGTTCCGGAGGAGGATACAGCTCTGGAAGCAGCAGTTATGGC
TCTGGAGGCCGACAGTCTGGCTCCAGAGGCGGTAGTGGAGGAGGAGGTTCTATCTCTGGA
GGAGGATATGGCTCTGGCGGTGGTTCTGGAGGAAGATACGGATCTGGTGGTGGCTCTAAG
GGAGGGTCCATCTCTGGAGGAGGATATGGCTCTGGAGGTGGAAAACACAGCTCTGGAGGT
GGCTCTAGAGGAGGCTCCAGCTCTGGAGGAGGATATGGCTCTGGAGGTGGGGGTTCTAGC
TCTGTAAAGGGTAGCTCAGGTGAAGCTTTTGGTTCCAGCGTGACCTTCTCTTTTAGATAA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00038</identifier>
            <name>Filament</name>
          </pfam>
          <pfam>
            <identifier>PF16208</identifier>
            <name>Keratin_2_head</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cornified envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intermediate filament</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>keratin filament</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cytoskeletal protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural constituent of cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural constituent of epidermis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cornification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intermediate filament organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>keratinization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>keratinocyte activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>keratinocyte development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>keratinocyte migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>keratinocyte proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peptide cross-linking</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skin epidermis development</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0003789</id>
      <name>C-Jun-amino-terminal kinase-interacting protein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A32315</ref-id>
            <pubmed-id>10733674</pubmed-id>
            <citation>Peus D, Beyerle A, Rittner HL, Pott M, Meves A, Weyand C, Pittelkow MR: Anti-psoriatic drug anthralin activates JNK via lipid peroxidation: mononuclear cells are more sensitive than keratinocytes. J Invest Dermatol. 2000 Apr;114(4):688-92. doi: 10.1046/j.1523-1747.2000.00934.x.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9UQF2" source="Swiss-Prot">
        <name>C-Jun-amino-terminal kinase-interacting protein 1</name>
        <general-function>Protein kinase inhibitor activity</general-function>
        <specific-function>The JNK-interacting protein (JIP) group of scaffold proteins selectively mediates JNK signaling by aggregating specific components of the MAPK cascade to form a functional JNK signaling module. Required for JNK activation in response to excitotoxic stress. Cytoplasmic MAPK8IP1 causes inhibition of JNK-regulated activity by retaining JNK in the cytoplasm and inhibiting JNK phosphorylation of c-Jun. May also participate in ApoER2-specific reelin signaling. Directly, or indirectly, regulates GLUT2 gene expression and beta-cell function. Appears to have a role in cell signaling in mature and developing nerve terminals. May function as a regulator of vesicle transport, through interactions with the JNK-signaling components and motor proteins (By similarity). Functions as an anti-apoptotic protein and whose level seems to influence the beta-cell death or survival response.</specific-function>
        <gene-name>MAPK8IP1</gene-name>
        <locus>11p12-p11.2</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>4.61</theoretical-pi>
        <molecular-weight>77523.56</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6882</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF074091</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>4426597</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9UQF2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>JIP1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>IB-1</synonym>
          <synonym>IB1</synonym>
          <synonym>Islet-brain 1</synonym>
          <synonym>JIP-1</synonym>
          <synonym>JIP1</synonym>
          <synonym>JNK MAP kinase scaffold protein 1</synonym>
          <synonym>Mitogen-activated protein kinase 8-interacting protein 1</synonym>
          <synonym>PRKM8IP</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019471|C-Jun-amino-terminal kinase-interacting protein 1
MAERESGGLGGGAASPPAASPFLGLHIASPPNFRLTHDISLEEFEDEDLSEITDECGISL
QCKDTLSLRPPRAGLLSAGGGGAGSRLQAEMLQMDLIDATGDTPGAEDDEEDDDEERAAR
RPGAGPPKAESGQEPASRGQGQSQGQSQGPGSGDTYRPKRPTTLNLFPQVPRSQDTLNNN
SLGKKHSWQDRVSRSSSPLKTGEQTPPHEHICLSDELPPQSGPAPTTDRGTSTDSPCRRS
TATQMAPPGGPPAAPPGGRGHSHRDRIHYQADVRLEATEEIYLTPVQRPPDAAEPTSAFL
PPTESRMSVSSDPDPAAYPSTAGRPHPSISEEEEGFDCLSSPERAEPPGGGWRGSLGEPP
PPPRASLSSDTSALSYDSVKYTLVVDEHAQLELVSLRPCFGDYSDESDSATVYDNCASVS
SPYESAIGEEYEEAPRPQPPACLSEDSTPDEPDVHFSKKFLNVFMSGRSRSSSAESFGLF
SCIINGEEQEQTHRAIFRFVPRHEDELELEVDDPLLVELQAEDYWYEAYNMRTGARGVFP
AYYAIEVTKEPEHMAALAKNSDWVDQFRVKFLGSVQVPYHKGNDVLCAAMQKIATTRRLT
VHFNPPSSCVLEISVRGVKIGVKADDSQEAKGNKCSHFFQLKNISFCGYHPKNNKYFGFI
TKHPADHRFACHVFVSEDSTKALAESVGRAFQQFYKQFVEYTCPTEDIYLE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019472|C-Jun-amino-terminal kinase-interacting protein 1 (MAPK8IP1)
ATGGCGGAGCGAGAAAGCGGCGGCCTGGGAGGGGGGGCCGCGTCCCCGCCCGCCGCCTCC
CCGTTCCTGGGGCTGCACATCGCTTCGCCTCCCAATTTCAGGCTCACCCATGACATCAGC
CTGGAGGAGTTTGAGGATGAAGACCTCTCGGAGATCACTGATGAGTGTGGCATCAGCTTA
CAGTGCAAAGACACCCTGTCCTTACGGCCCCCGCGCGCCGGGCTGCTCTCTGCGGGCGGC
GGCGGCGCGGGGAGCCGGTTGCAGGCCGAGATGCTGCAGATGGACCTGATCGACGCGACG
GGGGACACTCCCGGGGCCGAGGACGACGAGGAGGACGACGACGAGGAGCGCGCGGCCCGG
CGGCCGGGAGCGGGGCCGCCCAAGGCCGAGTCCGGCCAGGAGCCGGCGTCCCGCGGCCAG
GGCCAGAGCCAAGGCCAGAGCCAGGGCCCGGGCAGCGGGGACACGTACCGGCCCAAGCGG
CCCACCACGCTCAACCTCTTTCCGCAGGTGCCGCGGTCTCAGGACACACTGAATAATAAT
TCTCTGGGCAAAAAGCACAGTTGGCAGGATCGGGTGTCTCGATCATCCTCACCCCTGAAG
ACAGGGGAGCAGACACCACCGCATGAACACATCTGCCTGAGCGATGAGCTGCCCCCCCAG
AGCGGCCCCGCCCCCACCACAGATCGAGGCACCTCCACCGACAGCCCTTGCCGCCGCAGC
ACAGCCACCCAGATGGCACCTCCGGGTGGTCCCCCTGCTGCCCCGCCTGGGGGTCGGGGC
CACTCGCATCGAGACCGAATCCACTACCAGGCCGATGTGCGACTAGAGGCCACTGAGGAG
ATCTACCTGACCCCAGTGCAGAGGCCCCCAGACGCTGCAGAGCCCACCTCCGCCTTCCTG
CCGCCCACTGAGAGCCGGATGTCAGTCAGCTCCGATCCAGACCCTGCCGCCTACCCCTCC
ACGGCAGGGCGGCCGCACCCCTCCATCAGTGAAGAGGAAGAGGGCTTCGACTGCCTGTCG
TCCCCAGAGCGGGCTGAGCCCCCAGGCGGAGGGTGGCGGGGGAGCCTGGGGGAGCCGCCG
CCACCTCCACGGGCCTCTCTGAGCTCGGACACCAGCGCCCTGTCCTATGACTCTGTCAAG
TACACGCTGGTGGTAGATGAGCATGCACAGCTGGAGCTGGTGAGCCTGCGGCCGTGCTTC
GGAGACTACAGTGACGAGAGTGACTCTGCCACCGTCTATGACAACTGTGCCTCCGTCTCC
TCGCCCTATGAGTCGGCCATCGGAGAGGAATATGAGGAGGCCCCGCGGCCCCAGCCCCCT
GCCTGCCTCTCCGAGGACTCCACGCCTGATGAACCCGACGTCCATTTCTCCAAGAAATTC
CTGAACGTCTTCATGAGTGGCCGCTCCCGCTCCTCCAGTGCTGAGTCCTTCGGGCTGTTC
TCCTGCATCATCAACGGGGAGGAGCAGGAGCAGACCCACCGGGCCATATTCAGGTTTGTG
CCTCGACACGAAGACGAACTTGAGCTGGAAGTGGATGACCCTCTGCTAGTGGAGCTCCAG
GCTGAAGACTACTGGTACGAGGCCTACAACATGCGCACTGGTGCCCGGGGTGTCTTTCCT
GCCTATTACGCCATCGAGGTCACCAAGGAGCCCGAGCACATGGCAGCCCTGGCCAAAAAC
AGTGACTGGGTGGACCAGTTCCGGGTGAAGTTCCTGGGCTCAGTCCAGGTTCCCTATCAC
AAGGGCAATGACGTCCTCTGTGCTGCTATGCAAAAGATTGCCACCACCCGCCGGCTCACC
GTGCACTTTAACCCGCCCTCCAGCTGTGTCCTGGAGATCAGCGTGCGGGGTGTGAAGATA
GGCGTCAAGGCCGATGACTCCCAGGAGGCCAAGGGGAATAAATGTAGCCACTTTTTCCAG
TTAAAAAACATCTCTTTCTGCGGATATCATCCAAAGAACAACAAGTACTTTGGGTTCATC
ACCAAGCACCCCGCCGACCACCGGTTTGCCTGCCACGTCTTTGTGTCTGAAGACTCCACC
AAAGCCCTGGCAGAGTCCGTGGGGAGAGCATTCCAGCAGTTCTACAAGCAGTTTGTGGAG
TACACCTGCCCCACAGAAGATATCTACCTGGAGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00640</identifier>
            <name>PID</name>
          </pfam>
          <pfam>
            <identifier>PF14604</identifier>
            <name>SH3_9</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dentate gyrus mossy fiber</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrial membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>kinesin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>MAP-kinase scaffold activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase inhibitor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>JUN phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cyclin-dependent protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of intrinsic apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of JNK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of transcription, DNA-templated</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vesicle-mediated transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0004660</id>
      <name>Keratin, type I cytoskeletal 12</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L1935</ref-id>
            <title>Anthralin/dithranol in dermatology</title>
            <url>https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-4632.2012.05611.x</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q99456" source="Swiss-Prot">
        <name>Keratin, type I cytoskeletal 12</name>
        <general-function>Structural molecule activity</general-function>
        <specific-function>May play a unique role in maintaining the normal corneal epithelial function. Together with KRT3, essential for the maintenance of corneal epithelium integrity (By similarity).</specific-function>
        <gene-name>KRT12</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>53510.935</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:6414</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q99456</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>K1C12_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CK-12</synonym>
          <synonym>Cytokeratin-12</synonym>
          <synonym>K12</synonym>
          <synonym>Keratin-12</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0017500|Keratin, type I cytoskeletal 12
MDLSNNTMSLSVRTPGLSRRLSSQSVIGRPRGMSASSVGSGYGGSAFGFGASCGGGFSAA
SMFGSSSGFGGGSGSSMAGGLGAGYGRALGGGSFGGLGMGFGGSPGGGSLGILSGNDGGL
LSGSEKETMQNLNDRLASYLDKVRALEEANTELENKIREWYETRGTGTADASQSDYSKYY
PLIEDLRNKIISASIGNAQLLLQIDNARLAAEDFRMKYENELALRQGVEADINGLRRVLD
ELTLTRTDLEMQIESLNEELAYMKKNHEDELQSFRVGGPGEVSVEMDAAPGVDLTRLLND
MRAQYETIAEQNRKDAEAWFIEKSGELRKEISTNTEQLQSSKSEVTDLRRAFQNLEIELQ
SQLAMKKSLEDSLAEAEGDYCAQLSQVQQLISNLEAQLLQVRADAERQNVDHQRLLNVKA
RLELEIETYRRLLDGEAQGDGLEESLFVTDSKSQAQSTDSSKDPTKTRKIKTVVQEMVNG
EVVSSQVQEIEELM</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017501|Keratin, type I cytoskeletal 12 (KRT12)
ATGGATCTCTCCAACAACACCATGTCACTCTCAGTGCGCACCCCCGGACTGTCCCGGCGG
CTCTCCTCGCAGAGTGTGATAGGCAGACCCAGGGGCATGTCTGCTTCCAGTGTTGGAAGT
GGTTATGGGGGAAGTGCCTTTGGCTTTGGAGCCAGCTGTGGGGGAGGCTTTTCTGCTGCT
TCCATGTTTGGTTCTAGTTCCGGCTTTGGGGGTGGCTCCGGAAGTTCCATGGCAGGAGGA
CTGGGTGCTGGTTATGGGAGAGCCCTGGGTGGAGGTAGCTTTGGAGGGCTGGGGATGGGA
TTTGGGGGCAGCCCAGGAGGTGGCTCTCTAGGTATTCTCTCGGGCAATGATGGAGGCCTT
CTTTCTGGATCAGAAAAAGAAACTATGCAAAATCTTAATGATAGATTAGCTTCCTACCTG
GATAAGGTGCGAGCTCTAGAAGAGGCTAATACTGAGCTAGAAAATAAAATTCGAGAATGG
TATGAAACACGAGGAACTGGGACTGCAGATGCTTCACAGAGCGATTACAGCAAATATTAT
CCACTGATTGAAGACCTCAGGAATAAGATCATTTCAGCCAGCATTGGAAATGCCCAGCTC
CTCTTGCAGATTGACAATGCGAGACTAGCTGCTGAGGACTTCAGGATGAAGTATGAGAAT
GAACTGGCCCTGCGCCAGGGCGTAGAGGCCGACATCAATGGCCTGCGCCGGGTGCTGGAC
GAGCTGACCCTGACCAGGACCGACCTGGAGATGCAGATCGAGAGCCTGAACGAGGAGCTG
GCCTACATGAAGAAGAACCACGAGGATGAGCTCCAAAGCTTCCGGGTGGGCGGCCCAGGC
GAGGTCAGCGTAGAAATGGACGCTGCCCCCGGAGTGGACCTCACCAGGCTCCTCAATGAT
ATGCGGGCGCAGTATGAAACCATCGCTGAGCAGAATCGGAAGGACGCTGAAGCCTGGTTC
ATTGAAAAGAGCGGGGAGCTCCGTAAGGAGATTAGCACCAACACCGAGCAGCTTCAGTCC
AGCAAGAGCGAGGTCACCGACCTGCGTCGCGCCTTTCAGAACCTGGAGATCGAGCTACAG
TCCCAGCTCGCCATGAAGAAATCCCTGGAGGACTCCTTGGCCGAAGCCGAGGGCGATTAC
TGCGCGCAGCTGTCCCAGGTGCAGCAGCTCATCAGCAACCTGGAGGCACAGCTGCTCCAG
GTGCGCGCGGACGCAGAGCGCCAGAACGTGGACCACCAGCGGCTGCTGAATGTCAAGGCC
CGCCTGGAGCTGGAGATTGAGACCTACCGCCGCCTGCTGGACGGGGAGGCCCAAGGTGAT
GGTTTGGAGGAAAGTTTATTTGTGACAGACTCCAAATCACAAGCACAGTCAACTGATTCC
TCTAAAGACCCAACCAAAACCCGAAAAATCAAGACAGTTGTGCAGGAGATGGTGAATGGT
GAGGTGGTCTCATCTCAAGTTCAGGAAATTGAAGAACTAATGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00038</identifier>
            <name>Filament</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intermediate filament</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>structural molecule activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cornea development in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelium development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual perception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>